EA003130B1 - Катионные виросомы в качестве системы для переноса генетического материала - Google Patents
Катионные виросомы в качестве системы для переноса генетического материала Download PDFInfo
- Publication number
- EA003130B1 EA003130B1 EA199800992A EA199800992A EA003130B1 EA 003130 B1 EA003130 B1 EA 003130B1 EA 199800992 A EA199800992 A EA 199800992A EA 199800992 A EA199800992 A EA 199800992A EA 003130 B1 EA003130 B1 EA 003130B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- membrane
- group
- cell
- vesicle
- phosphatidylethanolamine
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 73
- 125000002091 cationic group Chemical group 0.000 title claims abstract description 62
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 43
- 239000000277 virosome Substances 0.000 title description 138
- 238000012546 transfer Methods 0.000 title description 10
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims abstract description 93
- 239000012528 membrane Substances 0.000 claims abstract description 90
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims abstract description 87
- 150000002632 lipids Chemical class 0.000 claims abstract description 81
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 62
- 239000003550 marker Substances 0.000 claims abstract description 58
- 230000004927 fusion Effects 0.000 claims abstract description 52
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 48
- 239000000243 solution Substances 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 47
- 239000000185 hemagglutinin Substances 0.000 claims abstract description 43
- 101710154606 Hemagglutinin Proteins 0.000 claims abstract description 42
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims abstract description 42
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims abstract description 42
- 101710176177 Protein A56 Proteins 0.000 claims abstract description 42
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 claims abstract description 38
- -1 succinimidyl Chemical class 0.000 claims abstract description 37
- 239000003599 detergent Substances 0.000 claims abstract description 29
- 238000009739 binding Methods 0.000 claims abstract description 27
- 230000027455 binding Effects 0.000 claims abstract description 26
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000012634 fragment Substances 0.000 claims abstract description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 18
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 18
- 108090000695 Cytokines Proteins 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 17
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims abstract description 17
- 239000013598 vector Substances 0.000 claims abstract description 17
- 102000004127 Cytokines Human genes 0.000 claims abstract description 16
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 16
- 239000000232 Lipid Bilayer Substances 0.000 claims abstract description 15
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 15
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 15
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 14
- 239000013612 plasmid Substances 0.000 claims abstract description 14
- 239000000872 buffer Substances 0.000 claims abstract description 13
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 claims abstract description 12
- 230000001588 bifunctional effect Effects 0.000 claims abstract description 12
- 239000003102 growth factor Substances 0.000 claims abstract description 12
- 238000006243 chemical reaction Methods 0.000 claims abstract description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 10
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 10
- 201000011510 cancer Diseases 0.000 claims abstract description 9
- YYELLDKEOUKVIQ-UHFFFAOYSA-N octaethyleneglycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCO YYELLDKEOUKVIQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229920000936 Agarose Polymers 0.000 claims abstract description 8
- 238000001042 affinity chromatography Methods 0.000 claims abstract description 8
- 239000000074 antisense oligonucleotide Substances 0.000 claims abstract description 8
- 238000012230 antisense oligonucleotides Methods 0.000 claims abstract description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 claims abstract description 8
- 239000013638 trimer Substances 0.000 claims abstract description 8
- 102000053642 Catalytic RNA Human genes 0.000 claims abstract description 7
- 108090000994 Catalytic RNA Proteins 0.000 claims abstract description 7
- 241001465754 Metazoa Species 0.000 claims abstract description 7
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 7
- 108091028664 Ribonucleotide Proteins 0.000 claims abstract description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 7
- 239000005547 deoxyribonucleotide Substances 0.000 claims abstract description 7
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims abstract description 7
- 230000001939 inductive effect Effects 0.000 claims abstract description 7
- 208000015181 infectious disease Diseases 0.000 claims abstract description 7
- 208000032839 leukemia Diseases 0.000 claims abstract description 7
- 235000021317 phosphate Nutrition 0.000 claims abstract description 7
- 239000002336 ribonucleotide Substances 0.000 claims abstract description 7
- 125000002652 ribonucleotide group Chemical group 0.000 claims abstract description 7
- 108091092562 ribozyme Proteins 0.000 claims abstract description 7
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 6
- 239000011159 matrix material Substances 0.000 claims abstract description 6
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims abstract description 6
- 230000002829 reductive effect Effects 0.000 claims abstract description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 5
- 125000003277 amino group Chemical group 0.000 claims abstract description 5
- 238000002523 gelfiltration Methods 0.000 claims abstract description 5
- 206010022000 influenza Diseases 0.000 claims abstract description 5
- 230000002062 proliferating effect Effects 0.000 claims abstract description 5
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 5
- 239000004793 Polystyrene Substances 0.000 claims abstract description 4
- 239000007979 citrate buffer Substances 0.000 claims abstract description 4
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 229920002223 polystyrene Polymers 0.000 claims abstract description 4
- 230000000284 resting effect Effects 0.000 claims abstract description 4
- 208000036142 Viral infection Diseases 0.000 claims abstract description 3
- 239000007853 buffer solution Substances 0.000 claims abstract description 3
- 239000007795 chemical reaction product Substances 0.000 claims abstract description 3
- 238000005227 gel permeation chromatography Methods 0.000 claims abstract description 3
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 3
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 230000009385 viral infection Effects 0.000 claims abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 38
- 238000002360 preparation method Methods 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 13
- 238000011534 incubation Methods 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 7
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 6
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 6
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 5
- PFNFFQXMRSDOHW-UHFFFAOYSA-N Spermine Natural products NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims description 5
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 5
- 230000002458 infectious effect Effects 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- ZQCIMPBZCZUDJM-UHFFFAOYSA-N 2-octoxyethanol Chemical group CCCCCCCCOCCO ZQCIMPBZCZUDJM-UHFFFAOYSA-N 0.000 claims description 4
- 229940063675 spermine Drugs 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 229920002684 Sepharose Polymers 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 238000011895 specific detection Methods 0.000 claims description 2
- 125000004035 thiopropyl group Chemical group [H]SC([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 238000002604 ultrasonography Methods 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- 239000002771 cell marker Substances 0.000 claims 2
- 229940053198 antiepileptics succinimide derivative Drugs 0.000 claims 1
- 239000012299 nitrogen atmosphere Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 171
- 230000003612 virological effect Effects 0.000 abstract description 15
- 108020004414 DNA Proteins 0.000 abstract description 13
- 230000008569 process Effects 0.000 abstract description 11
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 238000001514 detection method Methods 0.000 abstract description 5
- 108700020796 Oncogene Proteins 0.000 abstract description 4
- 108010093857 Viral Hemagglutinins Proteins 0.000 abstract description 4
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 abstract description 3
- 150000008298 phosphoramidates Chemical class 0.000 abstract description 3
- 230000000069 prophylactic effect Effects 0.000 abstract description 3
- 238000012377 drug delivery Methods 0.000 abstract description 2
- 239000004971 Cross linker Substances 0.000 abstract 5
- 239000011324 bead Substances 0.000 abstract 3
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 abstract 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 abstract 2
- 108091027075 5S-rRNA precursor Proteins 0.000 abstract 2
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 abstract 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- MCIDNMJNWYUTMB-UHFFFAOYSA-N n-tert-butyl-n'-tetradecyl-3-(tetradecylamino)propanimidamide Chemical compound CCCCCCCCCCCCCCNCCC(NC(C)(C)C)=NCCCCCCCCCCCCCC MCIDNMJNWYUTMB-UHFFFAOYSA-N 0.000 abstract 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 abstract 1
- 239000007995 HEPES buffer Substances 0.000 abstract 1
- 108700020978 Proto-Oncogene Proteins 0.000 abstract 1
- 102000052575 Proto-Oncogene Human genes 0.000 abstract 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 abstract 1
- 229910000397 disodium phosphate Inorganic materials 0.000 abstract 1
- 235000019800 disodium phosphate Nutrition 0.000 abstract 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 25
- 239000002502 liposome Substances 0.000 description 17
- 238000001890 transfection Methods 0.000 description 17
- 238000009579 opioid replacement therapy Methods 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 238000005755 formation reaction Methods 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 208000020816 lung neoplasm Diseases 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108090000288 Glycoproteins Proteins 0.000 description 8
- 102000003886 Glycoproteins Human genes 0.000 description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
- 201000005202 lung cancer Diseases 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 6
- 108010067390 Viral Proteins Proteins 0.000 description 6
- 210000001163 endosome Anatomy 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 238000000527 sonication Methods 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 4
- 230000012202 endocytosis Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- 241000712431 Influenza A virus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 208000004117 Congenital Myasthenic Syndromes Diseases 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 239000003012 bilayer membrane Substances 0.000 description 2
- 230000008275 binding mechanism Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 1
- LWAVGNJLLQSNNN-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-azidobenzoate Chemical compound C1=CC(N=[N+]=[N-])=CC=C1C(=O)ON1C(=O)CCC1=O LWAVGNJLLQSNNN-UHFFFAOYSA-N 0.000 description 1
- UHEPSJJJMTWUCP-NKCAIAFTSA-N (2s,3s,4s,5s)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(1-hydroxyethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.O1C[C@](O)(C)[C@@H](NC)[C@H](O)[C@@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N UHEPSJJJMTWUCP-NKCAIAFTSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OYDXRQHMSA-N 1-[(2r,4s,5s)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H]([14CH2]O)[C@@H](O)C1 IQFYYKKMVGJFEH-OYDXRQHMSA-N 0.000 description 1
- VHYRLCJMMJQUBY-UHFFFAOYSA-N 1-[4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCC1=CC=C(N2C(C=CC2=O)=O)C=C1 VHYRLCJMMJQUBY-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 101710121925 Hemagglutinin glycoprotein Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101900156543 Influenza A virus Neuraminidase Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- JCABVIFDXFFRMT-DIPNUNPCSA-N [(2r)-1-[ethoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] octadec-9-enoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC)OC(=O)CCCCCCCC=CCCCCCCCC JCABVIFDXFFRMT-DIPNUNPCSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical group ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- ITFGZZGYXVHOOU-UHFFFAOYSA-N n,n-dimethylmethanamine;methyl hydrogen sulfate Chemical compound C[NH+](C)C.COS([O-])(=O)=O ITFGZZGYXVHOOU-UHFFFAOYSA-N 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96107282 | 1996-05-08 | ||
| PCT/EP1997/002268 WO1997041834A1 (en) | 1996-05-08 | 1997-05-04 | Cationic virosomes as transfer system for genetic material |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA199800992A1 EA199800992A1 (ru) | 1999-06-24 |
| EA003130B1 true EA003130B1 (ru) | 2003-02-27 |
Family
ID=8222763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA199800992A EA003130B1 (ru) | 1996-05-08 | 1997-05-04 | Катионные виросомы в качестве системы для переноса генетического материала |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6210708B1 (enExample) |
| EP (1) | EP0902682A2 (enExample) |
| JP (1) | JP2000509404A (enExample) |
| KR (1) | KR100536983B1 (enExample) |
| CN (1) | CN1271992C (enExample) |
| AR (1) | AR007054A1 (enExample) |
| AU (1) | AU710170B2 (enExample) |
| BG (1) | BG102880A (enExample) |
| BR (1) | BR9709224A (enExample) |
| CA (1) | CA2253561A1 (enExample) |
| CO (1) | CO4600638A1 (enExample) |
| CZ (1) | CZ299809B6 (enExample) |
| EA (1) | EA003130B1 (enExample) |
| GT (1) | GT199700058A (enExample) |
| HR (1) | HRP970234B1 (enExample) |
| HU (1) | HUP9901790A3 (enExample) |
| ID (1) | ID17934A (enExample) |
| NO (1) | NO327726B1 (enExample) |
| NZ (1) | NZ332666A (enExample) |
| OA (1) | OA10916A (enExample) |
| PA (1) | PA8429201A1 (enExample) |
| PE (1) | PE65198A1 (enExample) |
| PL (1) | PL199201B1 (enExample) |
| SK (1) | SK152698A3 (enExample) |
| SV (1) | SV1997000032A (enExample) |
| TN (1) | TNSN97080A1 (enExample) |
| WO (1) | WO1997041834A1 (enExample) |
| ZA (1) | ZA973885B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030113347A1 (en) * | 1991-05-08 | 2003-06-19 | Schweiz. Serum- & Impfinstitut Bern | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them |
| AU9224398A (en) * | 1997-09-08 | 1999-03-29 | Promega Corporation | Method of (in vivo) transformation utilizing lipid vehicles |
| SE513149C2 (sv) * | 1997-12-05 | 2000-07-17 | Katarina Edwards | Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna |
| GB9813100D0 (en) * | 1998-06-18 | 1998-08-19 | Secr Defence | Method of forming liposomes |
| CA2388053A1 (en) * | 1999-10-08 | 2001-04-19 | Nika Health Products Limited | Cationic dosper virosomes |
| JP4112860B2 (ja) * | 1999-12-17 | 2008-07-02 | ショット アクチエンゲゼルシャフト | 乗員の拘束システムの誘導作動式点火カプセルおよび点火カプセル用のテスト回路 |
| EP1252897A4 (en) * | 2000-01-21 | 2003-07-30 | Hisamitsu Pharmaceutical Co | MEDICINES FOR GENE THERAPY |
| JP2004536607A (ja) * | 2001-07-23 | 2004-12-09 | オニックス ファーマシューティカルズ，インコーポレイティド | 標的化されたヒト癌細胞において選択的に複製するウイルス変異体 |
| KR100411234B1 (ko) * | 2001-08-14 | 2003-12-18 | 한국과학기술원 | 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법 |
| WO2003038103A1 (en) * | 2001-10-29 | 2003-05-08 | Atso Raasmaja | Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers |
| US20040028687A1 (en) * | 2002-01-15 | 2004-02-12 | Waelti Ernst Rudolf | Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues |
| US20040176283A1 (en) * | 2002-04-01 | 2004-09-09 | Robinson John A. | Methods and compositions for the design of synthetic vaccines |
| EA008497B1 (ru) * | 2002-11-21 | 2007-06-29 | Певион Биотех Лтд. | Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая |
| US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| US20090208478A1 (en) * | 2003-10-24 | 2009-08-20 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| AU2004297533B2 (en) | 2003-10-24 | 2010-04-29 | Gencia Corporation | Methods and compositions for delivering polynucleotides |
| US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
| US8062891B2 (en) | 2003-10-24 | 2011-11-22 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to plants |
| US8507277B2 (en) | 2003-10-24 | 2013-08-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides |
| DE102004057303A1 (de) * | 2004-11-26 | 2006-06-01 | Merck Patent Gmbh | Stabile Kristallmodifikationen von DOTAP Chlorid |
| US20070172520A1 (en) * | 2005-11-18 | 2007-07-26 | University Of South Florida | Immunotargeting of Nonionic Surfactant Vesicles |
| WO2009016433A2 (en) * | 2006-09-15 | 2009-02-05 | Ottawa Health Research Institute | Oncolytic rhabdovirus |
| KR101242113B1 (ko) * | 2010-10-22 | 2013-03-19 | 고마바이오텍(주) | 유전자 전달용 양이온성 센다이 ｆ／ｈｎ 바이로좀 복합체 |
| WO2013032643A2 (en) * | 2011-08-31 | 2013-03-07 | Dicerna Pharmaceuticals, Inc. | Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells |
| WO2013050048A2 (en) * | 2011-10-07 | 2013-04-11 | Skau Aps | Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped rna viruses |
| MX383392B (es) | 2016-09-27 | 2025-03-13 | Camurus Ab | Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta). |
| CN109055432B (zh) * | 2018-08-16 | 2020-10-13 | 南京科佰生物科技有限公司 | 慢病毒感染试剂及其制备方法与应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| PL296382A1 (en) * | 1991-02-02 | 1993-11-02 | Nika Health Products Ltd Li Li | Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system |
| CA2086831C (en) * | 1991-05-08 | 1999-03-16 | Reinhard Gluck | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them |
| AU3614493A (en) | 1992-02-04 | 1993-09-01 | Chiron Corporation | Non-toxic lipid vaccine formulations |
| US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
| WO1995002698A1 (en) * | 1993-07-12 | 1995-01-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
| ATE223701T1 (de) * | 1994-05-31 | 2002-09-15 | Inex Pharmaceutical Corp | Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen |
| FR2726764B1 (fr) | 1994-11-14 | 1997-01-31 | Pasteur Merieux Serums Vacc | Adjuvant pour composition vaccinale |
-
1997
- 1997-05-04 NZ NZ332666A patent/NZ332666A/xx unknown
- 1997-05-04 EP EP97921852A patent/EP0902682A2/en not_active Withdrawn
- 1997-05-04 CA CA002253561A patent/CA2253561A1/en not_active Abandoned
- 1997-05-04 KR KR1019980708906A patent/KR100536983B1/ko not_active Expired - Fee Related
- 1997-05-04 JP JP9539526A patent/JP2000509404A/ja active Pending
- 1997-05-04 SK SK1526-98A patent/SK152698A3/sk unknown
- 1997-05-04 AU AU27766/97A patent/AU710170B2/en not_active Ceased
- 1997-05-04 BR BR9709224A patent/BR9709224A/pt unknown
- 1997-05-04 HU HU9901790A patent/HUP9901790A3/hu unknown
- 1997-05-04 EA EA199800992A patent/EA003130B1/ru not_active IP Right Cessation
- 1997-05-04 CN CNB971962324A patent/CN1271992C/zh not_active Expired - Fee Related
- 1997-05-04 PL PL329853A patent/PL199201B1/pl not_active IP Right Cessation
- 1997-05-04 CZ CZ0361498A patent/CZ299809B6/cs not_active IP Right Cessation
- 1997-05-04 WO PCT/EP1997/002268 patent/WO1997041834A1/en not_active Ceased
- 1997-05-06 ZA ZA973885A patent/ZA973885B/xx unknown
- 1997-05-07 TN TNTNSN97080A patent/TNSN97080A1/fr unknown
- 1997-05-07 PE PE1997000354A patent/PE65198A1/es not_active Application Discontinuation
- 1997-05-07 CO CO97024481A patent/CO4600638A1/es unknown
- 1997-05-07 GT GT199700058A patent/GT199700058A/es unknown
- 1997-05-07 SV SV1997000032A patent/SV1997000032A/es unknown
- 1997-05-07 HR HR970234A patent/HRP970234B1/xx not_active IP Right Cessation
- 1997-05-08 AR ARP970101917A patent/AR007054A1/es not_active Application Discontinuation
- 1997-05-08 PA PA19978429201A patent/PA8429201A1/es unknown
- 1997-05-09 ID IDP971533A patent/ID17934A/id unknown
-
1998
- 1998-10-29 BG BG102880A patent/BG102880A/xx unknown
- 1998-11-04 NO NO19985137A patent/NO327726B1/no not_active IP Right Cessation
- 1998-11-06 OA OA9800214A patent/OA10916A/en unknown
-
1999
- 1999-10-08 US US09/414,872 patent/US6210708B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU710170B2 (en) | Cationic virosomes as transfer system for genetic material | |
| Wang et al. | Highly efficient DNA delivery mediated by pH-sensitive immunoliposomes | |
| JPH11506935A (ja) | ペプチド増強カチオン脂質トランスフェクション | |
| US9017695B2 (en) | Chimeric therapeutics, compositions, and methods for using same | |
| US20110293725A1 (en) | Chimeric therapeutics, compositions, and methods for using same | |
| WO1997041834B1 (en) | Cationic virosomes as transfer system for genetic material | |
| JP2001515051A (ja) | 核酸送達用の脂質−ポリアミド結合体および組成物 | |
| CN116018405A (zh) | Trem组合物及其相关方法 | |
| CA2621694A1 (en) | Pharmaceutical compositions for delivery of ribonucleic acid to a cell | |
| EP3461487A1 (en) | Compositions and methods for the delivery of mrna to hepatic cells | |
| WO2010042742A2 (en) | Chimeric therapeutics, compositions, and methods for using same | |
| AU778399B2 (en) | Cationic DOSPER virosomes | |
| Yanagihara et al. | Liposome-mediated gene transfer | |
| HK1021317A (en) | Cationic virosomes as transfer system for genetic material | |
| WO2025063214A1 (ja) | 核酸を内封したリガンド修飾脂質ナノ粒子の製造方法 | |
| Wang | Cytoplasmic delivery of macromolecules VIA pH-sensitive liposomes | |
| JP2006158314A (ja) | 化合物の細胞内導入用キャリア剤およびそれを用いた化合物の細胞内導入方法 | |
| Okada et al. | Liposome-mediated gene transfer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |